FindTrial
Sign In

Respimat

DEVICE13 trials

Sponsors

Boehringer Ingelheim, University of Crete, University of Saskatchewan

Conditions

AsthmaChronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic Obstructive

Phase 2

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01040403
Boehringer IngelheimPulmonary Disease, Chronic Obstructive
Start: 2010-01-31Updated: 2015-07-15
Olodaterol Bridging Study in Asthma
WithdrawnNCT01428622
Boehringer IngelheimAsthma
Start: 2011-10-31Updated: 2011-11-22
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02175342
Boehringer IngelheimPulmonary Disease, Chronic Obstructive
Start: 1998-03-01Updated: 2025-01-31

Phase 3

Tiotropium / Respimat One Year Study in COPD.
CompletedNCT00387088
Boehringer IngelheimPulmonary Disease, Chronic Obstructive
Start: 2006-09-30Updated: 2014-05-16
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01431287
Boehringer IngelheimPulmonary Disease, Chronic Obstructive
Start: 2011-09-30End: 2013-11-30Updated: 2015-07-16
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01431274
Boehringer IngelheimPulmonary Disease, Chronic Obstructive
Start: 2011-09-30End: 2013-09-30Updated: 2015-07-16
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
CompletedNCT01533935
Boehringer IngelheimPulmonary Disease, Chronic Obstructive
Start: 2012-02-29End: 2013-11-30Updated: 2015-09-15
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
CompletedNCT01533922
Boehringer IngelheimPulmonary Disease, Chronic Obstructive
Start: 2012-03-31End: 2013-11-30Updated: 2015-09-15
Japan Long-term Safety for Tiotropium Plus Olodaterol
CompletedNCT01536262
Boehringer IngelheimPulmonary Disease, Chronic Obstructive
Start: 2012-02-29End: 2013-09-30Updated: 2015-07-15
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
CompletedNCT01559116
Boehringer IngelheimPulmonary Disease, Chronic Obstructive
Start: 2012-03-31End: 2013-08-31Updated: 2015-07-16

Phase 4

Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge
CompletedNCT02622243
University of SaskatchewanAsthma
Start: 2015-11-30End: 2016-03-31Updated: 2016-04-20

Unknown Phase

Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients
CompletedNCT02331940
University of CreteChronic Obstructive Pulmonary Disease
Start: 2010-03-31End: 2014-09-30Updated: 2017-03-30
Re-usable Respimat® Soft MistTM Inhaler Study
CompletedNCT04011735
Boehringer IngelheimPulmonary Disease, Chronic Obstructive
Start: 2019-09-30End: 2020-02-13Updated: 2021-03-03

Related Papers

Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials
Advances in Therapy2020-11-1113 citations
Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.
2020-09-1738 citations
Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO<sup>®</sup>/DYNAGITO<sup>®</sup> Trials.
2020-08-1011 citations
&lt;p&gt;No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD&lt;/p&gt;
International Journal of COPD2020-08-016 citations
&lt;p&gt;Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD&lt;/p&gt;
International Journal of COPD2020-08-015 citations
Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials
Advances in Therapy2020-07-1522 citations
Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO<sup>®</sup> and OTEMTO<sup>®</sup> Studies.
2020-05-276 citations
Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.
2019-10-2519 citations
The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history
2019-09-282 citations
Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials
2019-09-28
Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.
2019-03-067 citations
Effect of tiotropium/olodaterol combination therapy on long-term heart rate and blood pressure in COPD patients
2018-09-151 citations
Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials
Respiratory Medicine2018-08-2823 citations
Long-term safety of tiotropium/olodaterol Respimat<sup>®</sup> in patients with moderate-to-very severe COPD and renal impairment in the TONADO<sup>®</sup> studies.
2018-06-014 citations
Long-Term Safety of Tiotropium/Olodaterol Respimat in Patients with Moderate-to-Very Severe COPD and Renal Impairment in the TONADO Studies
Pneumologie2018-02-211 citations
Long-Term Safety of Tiotropium/Olodaterol Respimat in Elderly Patients with Moderate to Very Severe COPD in the TONADO Studies
Pneumologie2018-02-21
β-Blockers in COPD: A Cohort Study From the TONADO Research Program.
2018-01-3122 citations
Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials
2017-09-011 citations
The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials
2017-09-01
Effects of Symptom Severity at Baseline on Lung-Funktion and SGRQ Responses in the OTEMTO Studies
Pneumologie2017-02-23

21 more papers not shown